WO2017047791A9 - ピペラジン化合物の新規結晶 - Google Patents

ピペラジン化合物の新規結晶 Download PDF

Info

Publication number
WO2017047791A9
WO2017047791A9 PCT/JP2016/077547 JP2016077547W WO2017047791A9 WO 2017047791 A9 WO2017047791 A9 WO 2017047791A9 JP 2016077547 W JP2016077547 W JP 2016077547W WO 2017047791 A9 WO2017047791 A9 WO 2017047791A9
Authority
WO
WIPO (PCT)
Prior art keywords
new crystal
piperazine compound
crystal
present
piperazine
Prior art date
Application number
PCT/JP2016/077547
Other languages
English (en)
French (fr)
Other versions
WO2017047791A1 (ja
Inventor
青木　真一
Original Assignee
大鵬薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK16846662.1T priority Critical patent/DK3351542T3/da
Priority to CA2999009A priority patent/CA2999009C/en
Priority to AU2016324121A priority patent/AU2016324121B2/en
Priority to MYPI2018700802A priority patent/MY193595A/en
Priority to US15/760,366 priority patent/US20180258069A1/en
Priority to PL16846662T priority patent/PL3351542T3/pl
Priority to RU2018113722A priority patent/RU2018113722A/ru
Application filed by 大鵬薬品工業株式会社 filed Critical 大鵬薬品工業株式会社
Priority to JP2017540028A priority patent/JP6944372B2/ja
Priority to MX2018003320A priority patent/MX2018003320A/es
Priority to BR112018003448-7A priority patent/BR112018003448A2/ja
Priority to ES16846662T priority patent/ES2901157T3/es
Priority to SG11201801295WA priority patent/SG11201801295WA/en
Priority to EP16846662.1A priority patent/EP3351542B1/en
Priority to CN201680054242.6A priority patent/CN108026068A/zh
Priority to KR1020187010338A priority patent/KR102587705B1/ko
Publication of WO2017047791A1 publication Critical patent/WO2017047791A1/ja
Publication of WO2017047791A9 publication Critical patent/WO2017047791A9/ja
Priority to PH12018500399A priority patent/PH12018500399A1/en
Priority to HK18107367.0A priority patent/HK1247921A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本発明が解決すべき課題は、保存安定性及び非吸湿性が良好で、特に再現性良く取得可能な結晶を提供することである。本発明は、４－（（１－メチルピロール－２－イル）－カルボニル）－Ｎ－（４－（４－モルホリン－１－イル－カルボニルピペリジン－１－イル）－フェニル）－１－ピペラジンカルボキサミド・１水和物の結晶を提供する。
PCT/JP2016/077547 2015-09-17 2016-09-16 ピペラジン化合物の新規結晶 WO2017047791A1 (ja)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP16846662.1A EP3351542B1 (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
AU2016324121A AU2016324121B2 (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
MYPI2018700802A MY193595A (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
US15/760,366 US20180258069A1 (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
PL16846662T PL3351542T3 (pl) 2015-09-17 2016-09-16 Nowy kryształ związku piperazyny
RU2018113722A RU2018113722A (ru) 2015-09-17 2016-09-16 Новый кристалл пиперазинового соединения
BR112018003448-7A BR112018003448A2 (ja) 2015-09-17 2016-09-16 A new crystal of a Piperazine compound
JP2017540028A JP6944372B2 (ja) 2015-09-17 2016-09-16 ピペラジン化合物の新規結晶
MX2018003320A MX2018003320A (es) 2015-09-17 2016-09-16 Cristal novedoso de compuesto piperazina.
DK16846662.1T DK3351542T3 (da) 2015-09-17 2016-09-16 Nyt krystal af piperazinforbindelse
ES16846662T ES2901157T3 (es) 2015-09-17 2016-09-16 Nuevo cristal de compuesto de piperazina
SG11201801295WA SG11201801295WA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
CA2999009A CA2999009C (en) 2015-09-17 2016-09-16 Crystal form of 4-((1-methylpyrrol-2-yl)-carbonyl)-n-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide monohydrate
CN201680054242.6A CN108026068A (zh) 2015-09-17 2016-09-16 哌嗪化合物的新晶体
KR1020187010338A KR102587705B1 (ko) 2015-09-17 2016-09-16 피페라진 화합물의 신규 결정
PH12018500399A PH12018500399A1 (en) 2015-09-17 2018-02-22 New crystal of piperazine compound
HK18107367.0A HK1247921A1 (zh) 2015-09-17 2018-06-06 哌嗪化合物的新晶體

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015184022 2015-09-17
JP2015-184022 2015-09-17

Publications (2)

Publication Number Publication Date
WO2017047791A1 WO2017047791A1 (ja) 2017-03-23
WO2017047791A9 true WO2017047791A9 (ja) 2017-05-18

Family

ID=58289428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/077547 WO2017047791A1 (ja) 2015-09-17 2016-09-16 ピペラジン化合物の新規結晶

Country Status (22)

Country Link
US (1) US20180258069A1 (ja)
EP (1) EP3351542B1 (ja)
JP (1) JP6944372B2 (ja)
KR (1) KR102587705B1 (ja)
CN (1) CN108026068A (ja)
AU (1) AU2016324121B2 (ja)
BR (1) BR112018003448A2 (ja)
CA (1) CA2999009C (ja)
DK (1) DK3351542T3 (ja)
ES (1) ES2901157T3 (ja)
HK (1) HK1247921A1 (ja)
HU (1) HUE057813T2 (ja)
MA (1) MA42839A (ja)
MX (1) MX2018003320A (ja)
MY (1) MY193595A (ja)
PH (1) PH12018500399A1 (ja)
PL (1) PL3351542T3 (ja)
PT (1) PT3351542T (ja)
RU (1) RU2018113722A (ja)
SG (2) SG10201912021VA (ja)
TW (1) TWI707851B (ja)
WO (1) WO2017047791A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024143236A1 (ja) * 2022-12-26 2024-07-04 大鵬薬品工業株式会社 酢酸エステル塩酸塩の結晶

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070614B (zh) * 2005-05-23 2014-01-15 诺华股份有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
BRPI1009212B8 (pt) * 2009-03-09 2024-03-12 Taiho Pharmaceutical Co Ltd Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica
US8765750B2 (en) * 2010-01-22 2014-07-01 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
JP6130701B2 (ja) * 2012-04-01 2017-05-17 エシャシ ファーマ リミテッドＥｓｈｙａｓｉ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ （２ｒｓ）−１−ジメチルアミノ−３−｛２−［２−（３−メトキシフェニル）エチル］フェノキシ｝プロパン−２−イルコハク酸水素塩酸塩の工業的製造方法
JP5999686B2 (ja) * 2012-04-05 2016-09-28 ロンシール工業株式会社 耐熱性ポリ乳酸系成形体、およびその製造方法
BR112015005489B1 (pt) * 2012-09-19 2022-07-12 Taiho Pharmaceutical Co., Ltd. Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas

Also Published As

Publication number Publication date
MX2018003320A (es) 2018-05-30
HUE057813T2 (hu) 2022-06-28
JP6944372B2 (ja) 2021-10-06
TW201720818A (zh) 2017-06-16
AU2016324121A1 (en) 2018-04-26
HK1247921A1 (zh) 2018-10-05
EP3351542A4 (en) 2019-04-24
EP3351542B1 (en) 2021-11-17
WO2017047791A1 (ja) 2017-03-23
DK3351542T3 (da) 2022-01-03
RU2018113722A3 (ja) 2019-12-23
CN108026068A (zh) 2018-05-11
CA2999009C (en) 2023-05-23
KR20180051628A (ko) 2018-05-16
PH12018500399A1 (en) 2018-08-29
PT3351542T (pt) 2021-12-21
MA42839A (fr) 2018-07-25
US20180258069A1 (en) 2018-09-13
EP3351542A1 (en) 2018-07-25
MY193595A (en) 2022-10-19
TWI707851B (zh) 2020-10-21
SG11201801295WA (en) 2018-03-28
KR102587705B1 (ko) 2023-10-12
CA2999009A1 (en) 2017-03-23
BR112018003448A2 (ja) 2018-09-25
JPWO2017047791A1 (ja) 2018-07-05
AU2016324121B2 (en) 2020-08-20
PL3351542T3 (pl) 2022-02-14
ES2901157T3 (es) 2022-03-21
RU2018113722A (ru) 2019-10-18
SG10201912021VA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL257390B (en) Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
CL2017001617A1 (es) Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas
MY192059A (en) Heterocyclic amides as kinase inhibitors
IL252368B (en) 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it
EP3260450A4 (en) Compound having saturated six-membered ring and alkoxy group or alkoxyalkyl group, liquid crystal composition and liquid crystal display element
WO2013192538A3 (en) Location graph based derivation of attributes
EP3387649A4 (en) PERFORMANCE OF ADDITIONAL UPDATE OPERATIONS DURING AN AUTOMATIC UPDATE MODE
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
SG11201506093SA (en) N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EA201691244A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
WO2014153495A9 (en) Novel stat3 inhibitors
PH12017500530B1 (en) Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
EP3162793A4 (en) Chiral resolution method of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
MX2018005803A (es) Forma novedosa de espirodiclofeno, procedimiento de preparacion y uso de la misma.
WO2014209515A3 (en) Determining locations of interest to a user
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
WO2017047791A9 (ja) ピペラジン化合物の新規結晶
EP3150587A4 (en) Deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl]piperazine compound or derivative thereof, and pharmaceutical composition and use thereof
EP3738961A4 (en) HETEROCYCLIC COMPOUND AS A CSF-1R INHIBITOR AND USE OF IT
PT2943488T (pt) Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
WO2016159666A3 (ko) 결정형 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16846662

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017540028

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201801295W

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 122021001601

Country of ref document: BR

Ref document number: 12018500399

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 15760366

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2999009

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/003320

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018003448

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20187010338

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016846662

Country of ref document: EP

Ref document number: 2018113722

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2016324121

Country of ref document: AU

Date of ref document: 20160916

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018003448

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180222